July 22: “If India runs negative real interest rate and has a large current account deficit, it will discourage foreign investors,” says Chetan Ahya, MD & Asia Pacific Economist at Morgan Stanley. He also reviews the impact of RBI liquidity tightening measures on growth and monetary policy.
July 22: The Street is not very happy with Reserve Bank of India’s moves to steady the rupee but Chetan Ahya, MD & Asia Pacific Economist at Morgan Stanley, says that the central bank is trying to convey that there is a limit to which it can allow rupee depreciation.
July 22: FICCI President Naina Lal Kidwai says, “Though NPAs coming off lows is good, we expect an increase in NPAs due to slowdown.” The twin deficits, especially the current account, and inflation remain the key economic concerns, she adds.
July 22: FICCI President Naina Lal Kidwai says, “Many power and oil & gas projects have been cleared, but there is a need to get cleared projects operationalised.” She tells Bloomberg TV India that states play a key role in project approvals.
July 22: “Given the fact that telecom is a debt-ridden sector; FDI move is welcome. There is a strong prospect of increased investment coming into telecom,” says Naina Lal Kidwai, the President of FICCI, adding that insurance will also benefit from the FDI cap hike.
July 22: “Though immediate effect of RBI move is on liquidity, we are fortunate that the central bank did not hike the repo rate,” FICCI President Naina Lal Kidwai says, while speaking about Corporate India’s take on RBI measures to tighten money rates.
GK Prasad discusses Dr. Anji Reddy’s vision of discovering new drugs & the state of the volatile Rupee in this segment of Inside India’s Best Known Companies.
Dr.Reddy’s Labs’ GK Prasad speaks about the early years and the evolution of the company. Listen to him speak to Bloomberg TV India’s Mini Menon about the setbacks that the company faced.
GK Prasad, Dr.Reddy’s Labs’ MD speaks to Bloomberg TV India’s Mini Menon about the growth drivers that will help the pharma giant grow. Also, listen to Accenture India’s Sriram Srinivasan analyse the potential for the Indian pharma industry.
BHARAT 22 ETF
Bank of Baroda
BHARAT 22 ETF
Pvt Sector 39%
PSU Stocks 61%
BHARAT 22 ETF
Second tranche to open today, 2.5% discount across categories
Government looking to raise up to Rs 8,400 Cr
Consists of stocks from six sectors
Hinduja Leyland Finance files for IPO
Hinduja Leyland Finance IPO to raise Rs 500 Cr
Sells shares of Titan Time products unit to Danlaw Tech
To receive Rs 18.5 Cr from unit
AVIATION IN FOCUS
Airports run out of slots, parking space
Delhi, Mumbai offering slots between 11 P.M & 5 A.M only
Pune & Goa not offering any slots for new flights
Bengaluru, Chennai & Kolkata don't have any slots in peak time
USFDA nod for Atovaquone & Proguanil Hydrochloride tablets
First supplemental ANDA from U.S. MFG facility
U.S. Facility to provide foundation for future product approvals
U.S. Facility peak capacity of 300-400 Mn tablets per year
Has invested more than $100 Mn into the U.S. Facility